Concordare raises seed round led by Surface Ventures to digitize trial protocols
What's the deal? Concordare TrialsDealroom has a profile for this one. Try Dealroom → has closed a seed round led by Surface VenturesDealroom has a profile for this one. Try Dealroom →, with participation from Techstars, Innovation WorksDealroom has a profile for this one. Try Dealroom →, Gaingels, and individual investors. The New York startup converts static clinical trial protocol PDFs into a structured, interoperable digital format that downstream systems can use.
Who's behind it? Founder and chief executive officer Zach Sawaged built the company after a decade across clinical research sites, sponsors, and technology vendors, with stints at NYU LangoneDealroom has a profile for this one. Try Dealroom →, AmgenDealroom has a profile for this one. Try Dealroom →, Johnson & JohnsonDealroom has a profile for this one. Try Dealroom →, TakedaDealroom has a profile for this one. Try Dealroom →, and VeevaDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The ConcordareDealroom has a profile for this one. Try Dealroom → Suite ingests any protocol PDF and converts it into the company's proprietary Clinical Trial Protocol Model (CTPM), a system-agnostic source of truth for a trial. AI handles extraction only; the model is human-reviewed before generating configurations and documents.
Why it matters: Manual configuration against lengthy, non-standardized protocols costs an estimated $25 million per study, according to the company. Concordare says its workflow can accelerate study activation by six to eight weeks.
What's the money for? The round backs product development, team expansion, and the growth of Concordare's site partnership network. Its partners include Rutgers UniversityDealroom has a profile for this one. Try Dealroom →, which uses the platform across multiple teams, and the company is contracting with additional institutions nationwide.
The signal: Backing from Surface Ventures, Techstars, and Gaingels points to investor interest in software that targets the structural inefficiencies at the center of clinical research. "By digitizing clinical trial protocols at an early point in the process, Concordare has the opportunity to further digitize the entire clinical trial value chain," said Gyan Kapur, co-managing partner at Surface Ventures.
Read more: lasvegassun.com
Image credit: Homedust
